by The global non-opioid pain treatment market is developing rapidly owing to growing preference for alternatives to opioids for pain management due to surge in side effects and abuse potential caused by prolonged opioid use. Non-opioid analgesics such as NSAIDs (nonsteroidal anti-inflammatory drugs), acetaminophen, antidepressants, and topical analgesics including patches and gels are commonly used for mild to moderate pain relief. These are effective in treating chronic pain related to conditions like arthritis, lower back pain, headaches.
The Global non-opioid pain treatment market is estimated to be valued at US$ 43.67 Bn in 2024 and is expected to exhibit a CAGR of 8.1% over the forecast period 2024 to 2031.
Key Takeaways
Key players operating in the global non-opioid pain treatment are Pfizer Inc., Teva Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Sun Pharmaceutical Industries Ltd., Cipla Inc., Fresenius Kabi AG, GSK, Vertex Pharmaceuticals Incorporated, Pacira BioSciences, Collegium Pharmaceuticals, Cara Therapeutics, Akelos, Fidia Farmaceutici S.p.A., Sanofi, Eli Lilly and Company, Merck Co, Acorda Therapeutics, Hyloris Pharmaceuticals, Hikma Pharmaceuticals PLC. Major players are engaged in product innovation, facility expansion and new product launches to gain ground in the market.
The Global Non Opioid Pain Treatment Market Size provides significant growth opportunities owing to rising prevalence of chronic pain conditions such as arthritis, lower back pain, headaches. Market players are investing in R&D of novel non-opioid therapies to expand product offerings.
Growing awareness and demand for non-addictive treatments in emerging markets of Asia Pacific and Latin America will drive market expansion globally over the forecast period.
Market drivers
Stringent regulations limiting the prescription of opioid drugs for chronic pain management are a major driver for non-opioid pain treatment market growth. For instance, the US FDA in 2016 and Canada in 2017 enforced guidelines for judicious opioid prescription. This has shifted focus onto alternative therapies. Also, non-opioid drugs have better safety profiles and carry minimal risk of dependence, driving their adoption.
PEST Analysis
Political: Regulations and laws regarding opioid usage and prescription have become more stringent in many countries due to addiction and abuse concerns. This has positively impacted demand for effective non-opioid alternatives for pain management.
Economic: Rising healthcare costs and need for more cost effective treatments have increased demand for non-opioid drugs that avoid adverse effects and risks associated with opioids.
Social: Growing awareness about risks of opioid addiction and abuse has made patients and doctors more open to considering effective non-opioid options. Lifestyle diseases and aging population have contributed to rising social need for pain relief solutions.
Technological: Advancements in drug delivery systems, formulation development and biologics research have enabled development of novel targeted therapies with greater efficacy and improved safety profiles compared to earlier generation non-opioid medications. Continuous R&D efforts are expanding the pipeline of treatment choices.
The geographical regions where the global non-opioid pain treatment market in terms of value is concentrated include North America and Europe. Stringent regulations related to opioid prescription and widespread availability of advanced healthcare infrastructure have supported early adoption of alternative therapies in these developed markets.
The Asia Pacific region represents the fastest growing geographical segment for the global non-opioid pain treatment market. Factors such as rising geriatric population, growing penetration of private healthcare insurance, increasing governmental support for healthcare sector development and economic growth in countries like India and China are bolstering demand growth. Rising clinical research activities in the region are also expanding treatment access.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
